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§  Alpha-N-acetylgalactosaminidase (nagalase) accumulates in serum of cancer patients and is responsible 
for deglycosylation of vitamin D binding protein (Gc-protein), which is the precursor of vitamin D 
binding protein-derived macrophage activating factor (GcMAF).  
§  Deglycosylated vitamin D binding protein cannot be converted into GcMAF and decreased endogenous 
GcMAF production contributes to immunodeficiency in advanced cancer patients. 
§  The increase in nagalase activity in cancer patients is due to the fact that cancer cells release nagalase and, 
therefore, nagalase activity reflects tumor burden, aggressiveness and progression of the disease.  
§  Determination of nagalase activity is currently proposed as a reliable way of evaluation of cancer severity. 
 
§  In serum, nagalase acts as endo-nagalase and it is unable to deglycosylate a monosaccharide,                    
N-acetylgalactosamine (GalNAc), of GcMAF and, therefore, it is unable to degrade exogenously 
administered GcMAF.  
§  This led to the proposal of administering GcMAF to patients with elevated nagalase activity. 
§  It was observed that GcMAF exerts multiple anti-cancer effects in vivo and in vitro, both in experimental 
and in spontaneous tumours. The anti-cancer effects of GcMAF are often referred to as ?immunotherapy?. 
§  In the clinical cases presented here, we report examples of the results that have been obtained 
administering GcMAF to breast cancer patients with particular focus on the effects of GcMAF on serum 
nagalase activity.  
§  In addition, we report the direct effects of GcMAF on human breast cancer cells in culture. 
Direct effects of GcMAF on human breast cancer cells. 
 
§  MCF-7 cells were starved in serum-free medium for 24 h and incubated with GcMAF for 
further 24 h. At the end of the incubation period, cells were fixed and stained and the plates 
were photographed under a microscope at low magnification to appreciate the formation of 
the typical cancer cell clusters. GcMAF was dissolved in a solvent designed to fit its 
molecular structure; in particular, the solvent was designed to fit the hydrophobic domains 
binding vitamin D and fatty acids as well as the hydrophilic domain where GalNAc is 
attached to threonine at position 420. ↑  Upper panel: Control. Human breast cancer cells form several clusters. Each cluster is 
formed by about 40 cells. 
↓  Lower panel: GcMAF (0.2 ng/ml; 4 pM). The dramatic reduction in clusters is clearly 
evident. Once dissolved in this particular solvent adapted to its molecular structure, GcMAF 
exerted a powerful anti-cancer effect at extremely low concentration. 
 
The number of human breast cancer cell clusters with an area larger than 20.000 square microns 
was significantly reduced after incubation with 4 pM GcMAF. 
 
The size of each individual cell, however, was not changed and in control plates as well as in 
GcMAF treated plates, the average size of human breast cancer cells was about 530 square 
microns.  
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in vitro  
Clinical Cases # 1 
Female, born 1947. Carcinoma of left breast (found on survey), 
operated with sentinel nodes in 2010, chemotherapy 4 of 6 series, no 
specific complaints left. Still some malaise, fatigue and sleep-disorder. 
Nagalase level at presentation on August 9, 2011: 1.70. January 16, 
2012: 1.00. March 12, 2012: 0.72. December 11, 2012: 0.60. GcMAF-
treatment (predominantly intravenous route) combined with 
acupuncture. GcMAF discontinued in April 2012. Aspecific 
complaints diminished. Patient still seen every few months. A 
significant decrease of nagalase level can be observed after 5 months 
of treatment. Such a decrease continued after interruption of GcMAF 
treatment, reaching normal values about 16 months since the 
beginning of the treatment. According to the literature, normalization 
of nagalase level in breast cancer patients is considered an index of 
eradication of the tumour burden. 
	  
Clinical Cases # 2 
Female, born 1950. Carcinoma of left breast, specific complaints, 
metastases probable. After local operation, irradiation of thorax, 
combined with chemotherapy, Herceptin-therapy. Partly 
complaints in association with treatments. Nagalase level at 
presentation on May 11, 2011: 5.60. October 6, 2011: 2.90. 
February 21, 2012: 1.80. October 18, 2012: 1.10. Treated with 
intramuscular, later intravenous GcMAF, and a few acupuncture-
treatments. No further complaints (subsided in 3-6 weeks), still in 
intravenous GcMAF-regime. A significant decrease of nagalase 
level can be observed after 5 months. After about 17 months of 
GcMAF treatment, nagalase levels are approaching normal 
values.  
in vivo 
➼  The observation reported here confirm and extend the results 
presented in (Int J Cancer. 2008 Jan 15;122(2):461-7; Cancer 
Immunol Immunother. 2008 Jul;57(7):1007-16; Transl Oncol. 
2008 Jul;1(2):65-72; J Med Virol. 2009 Jan;81(1):16-26; 
Autism Insights 2012:4 31–38; Anticancer Res. 2013 Jul;33
(7):2917-9), and further stress the role of GcMAF in the 
immunotherapy of cancer and other chronic diseases.  
➼  The results presented here on breast cancer are consistent 
with the results obtained in a series of patients with advanced 
cancer treated with GcMAF. 
➼  The interest in the 
effects of GcMAF on 
human breast cancer 
cells is further 
demonstrated by the fact 
that a recent paper on 
this topic has been 
ranked in the top 5% of 
all scientific articles ever 
tracked by Altmetric.  
 
➼  In conclusion, the results presented here support and 
reinforce the hypothesis that GcMAF treatment could 
become part of an integrated immunotherapy of breast 
cancer. 
•  Highly purified, activity-tested GcMAF was obtained from Immuno Biotech Ltd, Guernsey, Channel Isles. Common 
reagents were from Sigma Aldrich (Milan, Italy). Gc-protein was used as control. 
•  Human breast cancer cells (cell line MCF-7) were obtained from the Istituto Zooprofilattico Sperimentale della 
Lombardia e dell?Emilia-Romagna, Brescia, Italy.  
•  A retrospective chart review for analysis of nagalase testing was accomplished on the initial cohort of patients tested by 
the treating clinicians All records were reviewed by physicians for confirmation of test results, confirmed diagnoses, the 
time intervals between testing, the dosing of subsequent GcMAF used and the observed clinical responses. The oncologic 
diagnosis was confirmed by other treating physicians. 
 
•  Administration of GcMAF to individual patients was performed exclusively by their treating physicians (Robert Eslinger, 
MD, Reno Integrative Medical Center; Reno, NV, USA, and Steven Hofman, MD, CMC-Capelle a/d Ijssel, The 
Netherlands) according to the rules and regulations of each respective Country. The original clinical records are conserved 
by the physicians in their respective locations as indicated.  
 
•  Nagalase testing. Although nagalase is not specific for any particular histological type of cancer, nevertheless, its decrease 
following GcMAF treatment is considered an index of the therapeutic efficacy of GcMAF since nagalase activity is 
proportional to tumour burden. Nagalase testing was performed at ELN Laboratories (Bunnik, The Netherlands) following 
the procedure published  by Yamamoto et al. Nagalase activity was determined by using an endpoint enzymatic assay 
using a chromogenic substrate. ELN Laboratories established a reference range of 0.32–0.95 nM/min/mg of substrate 
based on serum collected from healthy volunteers, a range slightly higher than that previously reported which was 
between 0.35 and 0.65 nM/min/mg. Further studies on higher numbers of subjects will establish which reference range is 
more appropriate. In any case, since all determinations were performed in the same laboratory, a relative decrease of 
nagalase following GcMAF administration was therefore used as an index of its therapeutic efficacy. 
